1. Introduction {#sec1}
===============

Cardiac arrest due to PE is a lethal condition \[[@B1]--[@B5]\]. Thrombolytics have been used successfully, mostly late in CPR after initial unresponsiveness to traditional advanced cardiac life support (ACLS) \[[@B6]--[@B11]\]. Recent resuscitation guidelines advocate using alteplase in PE related cardiac arrest \[[@B12]--[@B17]\]. There are no clear guidelines or protocols for the administration of thrombolytics during CPR. We present an approach of double bolus therapy during CPR guided by focused bedside echocardiography. This case suggests the potential benefit of using bedside echocardiography to guide the administration of a second bolus of alteplase given the excellent outcome in this case.

2. Case Report {#sec2}
==============

A 56-year-old, previously healthy Caucasian female presented to the emergency department (ED) with acute, severe shortness of breath and pleuritic chest pain for two hours with pulse of 140/min and respiratory rate of 30/min. She had undergone total right knee replacement surgery two weeks prior. She was taking aspirin 81 mg twice daily but no other medications and had no other medical history. She was brought in via ambulance in severe respiratory distress, diaphoretic, and a room air oxygen saturation of 70% and complained "I cannot breathe." There was some bruising at the surgical site and a small right knee effusion, but the surgical site was well healed with no erythema or purulence. Her electrocardiogram (ECG) showed sinus tachycardia without any acute ischemic changes.

She was immediately given 5000 units of intravenous heparin due to the high suspicion of pulmonary embolism. Her oxygen saturations remained around 70--79% despite receiving 100% oxygen (15 L) via nonrebreather mask. Arterial blood gas (ABG) on 100% oxygen showed (pH 6.8, pCO2 58.6, and PaO2 188) severe acidosis with an elevated A-a gradient of 334.8 mmHg. Patient was emergently intubated due to persistent respiratory distress, increased work of breathing, continued air hunger, and worsening respiratory acidosis with hypercapnia despite being on 100% oxygen via nonrebreather mask. She was given etomidate and succinylcholine and intubated without difficulty.

Shortly after intubation, she underwent cardiac arrest with pulseless electrical activity (PEA). Immediate CPR was started. She received 50 mEq intravenous (IV) sodium bicarbonate, 1 mg of IV epinephrine, and 1 mg of IV atropine with four cycles of chest compression during first round of resuscitation. Emergent bedside echocardiogram was performed at the first pulse check and showed a severely dilated right ventricle (RV), with reduced right ventricular systolic function and normal left ventricular (LV) size and systolic function. These findings were suggestive of a massive PE ([Figure 1](#fig1){ref-type="fig"} and videos [1](#supplementary-material-1){ref-type="supplementary-material"}, [2](#supplementary-material-1){ref-type="supplementary-material"}). The first bolus of alteplase 50 mg IV was given at the fifth minute into CPR with ongoing chest compression. She had return of spontaneous circulation (ROSC) one minute following the t-PA bolus. However, she went into cardiac arrest again, approximately at 15 minutes into the code with recurrent PEA. During the second round of resuscitation, she received 1 mg of epinephrine with three cycles of chest compression and had ROSC after four minutes of CPR.

However, despite achieving the ROSC, she was hypotensive and therefore norepinephrine infusion was started. Echocardiogram was still showing persistent evidence of RV dysfunction with normal LV function. Given her persistent hemodynamic compromise with recurrent cardiac arrest, the decision was made to administer a second bolus of 50 mg alteplase, which was given at 24 minutes into the code. She developed PEA for a third time approximately at 29 minutes into the code. During third round of resuscitation, she received 1 mg of epinephrine and had ROSC. She required CPR for a total of 32 minutes, with three rounds of resuscitation and 2 IV boluses of 50 mg alteplase, 20 minutes apart. Her chest X-ray at this point showed bilateral perihilar opacities with mild cardiomegaly, consistent with pulmonary edema. Her other laboratory findings are summarized in the table ([Table 1](#tab1){ref-type="table"}).

After the third round of CPR, she also received a transfusion of two units of packed red blood cells via Belmont rapid infuser due to anemia. Bicarbonate infusion was initiated due to severe acidosis. Full dose heparin anticoagulation was started per postthrombolytics protocol. Some ecchymosis and swelling were noticed at the recent knee surgical site but she did not develop any significant bleeding complications after thrombolytic therapy. Venous Doppler ultrasound was done later which was positive for deep venous thrombosis in the gastrocnemius and popliteal veins of the right lower extremity. She was then transferred to the intensive care unit where bronchoscopy showed small pink frothy septum consistent with pulmonary edema but no evidence of aspiration.

Repeat echocardiogram the next day showed improvement in RV size and function ([Figure 2](#fig2){ref-type="fig"} and [video 3](#supplementary-material-1){ref-type="supplementary-material"}). She remained on vasopressor support, bicarbonate infusion, and epoprostenol (continuous inhalation at a rate of 360 mcg/hour) due to hypotension, acidosis, and hypoxia, respectively, which were titrated off over 24 hours.

Subsequent computed tomography angiogram of the chest performed eighty-four hours after CA showed segmental PE in right middle and left lower lobe with scattered air space opacities, atelectasis, and pleural effusions ([Figure 3](#fig3){ref-type="fig"}).

She had an excellent outcome without any neurologic sequelae or any bleeding complications. She was liberated from mechanical ventilation on hospital day 3 and supplemental oxygen was gradually weaned from high flow nasal cannula to room air by the time of discharge. Apixaban was initiated on hospital day 3. She was discharged home on hospital day 5, ambulating independently, on room air and on apixaban. On 3 months\' follow-up, she had complete normalization of right ventricular size and systolic function without any residual pulmonary hypertension (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"} and videos [4](#supplementary-material-1){ref-type="supplementary-material"}, [5](#supplementary-material-1){ref-type="supplementary-material"}).

3. Discussion {#sec3}
=============

Pulmonary embolism is the third most frequent cardiovascular disease in the United States (US) and has an extremely high morbidity and mortality \[[@B1]--[@B3]\]. Massive pulmonary embolism can cause cardiac arrest in 41% of cases and this is the major predictor of PE related mortality, which ranges from 65% to 95% \[[@B4], [@B5]\]. Pulmonary embolism is responsible for 2% to 15% of unexpected sudden deaths \[[@B4], [@B5]\], 2% of all cardiac arrests (CA) cases, and 6.5% of CA cases of extracardiac origin \[[@B5]\]. Moreover, in clinical setting, pulmonary embolism is often not suspected and is underestimated as a cause of acute cardiopulmonary collapse \[[@B18], [@B19]\].

Massive PE causes sudden increase in pulmonary vascular resistance (PVR) and mean pulmonary arterial pressure (mPAP) which is proportional to degree of obstruction in patients without preexisting pulmonary vascular disease \[[@B1]\]. It leads to increased RV wall tension and RV failure \[[@B21]\]. Eventually it leads to obstructive cardiogenic shock due to decrease in LV preload \[[@B22]\]. Presence of RV hypokinesis in patients with acute PE is associated with significantly increased mortality and a 14% risk for having a recurrent PE \[[@B2], [@B23], [@B24]\]. Massive PE can cause acute myocardial infarction (AMI) \[[@B25]\]. Massive PE can also lead to various types of cardiac arrhythmias including PEA, asystole, and ventricular fibrillation \[[@B26]--[@B31]\].

Traditional ACLS and CPR have been the common practice for PE related cardiac arrest \[[@B32], [@B33]\]. Vasopressor support and anticoagulation are used as well. However, only heparinization will not affect the clot burden and hemodynamic insult acutely. Systemic thrombolytic agents can minimize clot burden by clot lysis and can decrease the risk of recurrent Pes, and therefore long term pulmonary hypertension \[[@B34]\]. However, majority of benefit from thrombolytic therapy in patients with pulmonary embolism is limited to hemodynamic compromise \[[@B35]\], and fibrinolytics are not recommended in normotensive patients \[[@B36]\]. Catheter guided clot lysis can be considered in case of contraindication to systemic thrombolysis. Surgical embolectomy is reserved for unstable patients who have failed maximal medical treatment or in case of contraindication to thrombolytics \[[@B37]\].

Unfortunately, there are no strong prospective studies to show a survival benefit for the use of fibrinolytic drugs in cardiac arrest due to massive PE. Two available randomized control trials have failed to show a statistically significant outcome \[[@B38], [@B39]\]. However, these studies had various limitations such as late administration of thrombolytics and small sample size. Overall, in clinical practice, systemic thrombolytic therapy is less frequently used for a multitude of reasons; they include (a) limited evidence, (b) risk of bleeding with high dose of thrombolytics \[[@B40]\], (c) especially having ongoing CPR \[[@B41]\], and (d) lack of specific guidelines regarding thrombolytic dosing and timing.

Thrombolytic therapy also carries 9--22% risk of major bleeding, including a 1--5% risk of intracranial hemorrhage \[[@B2], [@B34], [@B41]--[@B44]\]. A nonrandomized study suggested a relative contraindication to thrombolytic use for CPR duration \> 10 minutes. This study analyzed use of thrombolytics in cardiac arrest due to AMI and concluded that thrombolysis could safely be applied to patients who undergo a CPR of \<10 min. They did not include patients with CPR \> 10 mins in their study \[[@B38]\]. Janata et al. in their study showed that CPR duration of \>10 min did not have any impact on major bleeding complications in patients receiving thrombolytic therapy \[[@B6]\].

There have been numerous cases reported in American and European literature, where thrombolysis (various formulations and regimens) was used in confirmed PE or clinically suggestive history of PE related cardiac arrest cases. Thrombolytic therapy has showed very favorable outcomes even when administered late during the CPR and as slow infusions after a prolonged CPR \[[@B6]--[@B11], [@B25]--[@B27]\]. Even though the available evidence for the utility of thrombolytics in such instances is of low quality, but due to the extremely high mortality of PE related cardiac arrest and frequently reported success with thrombolytics, its use is being advocated in recent resuscitation guidelines \[[@B12]--[@B17]\].

Unfortunately, there is no consensus regarding the dosage and timing of thrombolytics during resuscitation. The American Heart Association (AHA) recommends a two-hour infusion of 100 mg of alteplase in those with hemodynamic compromise. However, they do not clearly address the issue of cardiac arrest \[[@B15]\]. The European Resuscitation Council (ERC) and European Society of Cardiology (ESC) recommend a dose of 100 mg alteplase over 2 hours or 0.6 mg/kg over 15 minutes, though again they do not specifically address the approach in cardiac arrest \[[@B12]\]. The British Thoracic Society in 2003 recommended a 50 mg bolus of IV alteplase, which is the regimen most frequently used in recent published literature \[[@B10], [@B14], [@B16], [@B17]\].

However, there is no existing consensus or established guidance for subsequent approach. Surgical embolectomy or catheter guided interventions can be considered for unstable patients or those who have failed maximal medical treatment \[[@B35], [@B37]\]. Fengler and Brady in their review suggested administering a second bolus of alteplase \[[@B45]\].

We used focused bedside echocardiogram in our patient, as she was hemodynamically unstable and was experiencing recurrent cardiac arrest. Based on our echocardiogram findings of persistent RV dysfunction and dilatation with persistent hemodynamic compromise, we administered second bolus of t-PA with excellent outcome. This emphasizes the potential implacability of echocardiography for decision-making in such situations.

Echocardiography has limited sensitivity and specificity for the diagnosis of acute PE \[[@B46]\]. However, transthoracic echocardiography can be helpful to identify acute PE related right ventricular dysfunction \[[@B47]\]. Echocardiographic findings of RV strain include dilation of RV, flattened interventricular septum (D-sign of interventricular septal shift), and the classic sign of RV apical wall hypercontractility with hypokinesis of the RV free wall and base termed as "McConnell" sign \[[@B47]--[@B49]\]. McConnell sign is only 77% sensitive but has a specificity of 94% for acute PE, as RV failure due to chronic pulmonary hypertension typically shows global hypokinesia \[[@B49]\].

Presence of RV strain has more than twofold increase in risk of early mortality compared with patients with no signs of RV strain \[[@B35]\]. Use of echocardiography in diagnosis and management of hemodynamically unstable patients have also been recommended by the ESC \[[@B51]\]. A recent study showed that the average time from beginning of CPR to get a suitable echo image was 3.9 minutes (17 seconds to 10 minutes) \[[@B52]\].

We used focused echocardiography to guide repeat alteplase bolus administration, as our patient remained hemodynamically unstable, despite successful ROSC after initial alteplase bolus. Fortunately, despite prolonged CPR, our patient had an excellent outcome with no cardiac or neurologic sequela. At three months\' follow-up, the patient had complete normalization of right RV function without any residual pulmonary hypertension (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"} and videos [4](#supplementary-material-1){ref-type="supplementary-material"}, [5](#supplementary-material-1){ref-type="supplementary-material"}).

4. Conclusion {#sec4}
=============

Recent resuscitation guidelines recommend using thrombolytic therapy during resuscitation in cases of CA due to massive PE \[[@B1], [@B15]--[@B19]\]. Most consistently applied approach is 50 mg intravenous alteplase early during CPR. There is no existing consensus on subsequent approach. We present a case of double bolus alteplase guided by focused bedside echocardiography. Echocardiographic evidence of persistent RV dysfunction and dilatation in the setting of persistent hemodynamic instability, recurrent arrest, or even failure to achieve ROSC with initial bolus may warrant the administration of second bolus of alteplase. Future well-designed trials are needed to establish guidelines for thrombolytic therapy in CA to maximize safety and efficacy.
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###### 

Videos  1, 2: transthoracic echocardiogram during the CPR before administration of t-PA, showing a severely dilated right ventricle (RV) with reduced systolic function. RV free wall is hypokinetic and apical wall is hypercontractile (McConnell sign). There is flattening of interventricular septum with paradoxical motion of septum in diastole towards left ventricle (D-shaped left ventricle) consistent with significant RV overload. There is a dilated right atrium and moderate tricuspid regurgitation. Left ventricular size and systolic function are normal. Video  3: transthoracic echocardiogram 24 hours after t-PA administration, showing improvement in RV size and function but still dilated. Videos  4-5: transthoracic echocardiogram after 3 months showing interval normalization of right ventricular size and function. Right ventricular systolic pressure has also normalized.

###### 

Click here for additional data file.

![Transthoracic echocardiogram obtained before administration of t-PA: apical views showing a severely dilated right ventricle (RV) with reduced right ventricular systolic function. RV free wall is hypokinetic and RV apical wall is hypercontractile (arrow; McConnell sign). Left ventricular size and systolic function are normal.](CRICC2018-7986087.001){#fig1}

![Transthoracic echocardiogram 24 hours after t-PA administration: showing improvement in RV size (arrow) and function but still dilated.](CRICC2018-7986087.002){#fig2}

![CT angiogram showing pulmonary embolism (arrow).](CRICC2018-7986087.003){#fig3}

![](CRICC2018-7986087.004){#fig4}

###### 

Patient characteristics.

  Variable                                 Value           Target range
  ---------------------------------------- --------------- --------------------
  Pulse                                    140/minute      60--100/minute
  Respiratory rate                         34--50/minute   12--14/minute
  Blood pressure                           109/67 mmHg     120/80 mmHg
  Temperature                              97°F            97--99°F
  Oxygen saturation                                         
   Room air                                70%             88--100%
   100% oxygen                             70--79%         88--100%
  ABG on 15 L oxygen nonrebreather (NRB)                    
   Ph                                      6.8             7.4
   pO2                                     188 mmHg        100 mmHg
   pCO2                                    58.6 mmHg       40 mmHg
   HCO3                                    9.2 mmol/L      25 mmHg
  Laboratory data                                           
   WBC                                     4.5 × 10^9^/L   4--10 × 10^9^/L
   Neutrophil                              73%             50--60%
   Hemoglobin                              7.2 g/dl        12--14 g/dl
   Hematocrit                              22.83%          35--45%
   Platelets                               133 × 10^9^/L   130--450 × 10^9^/L
   Sodium                                  140 mEq/L       135--145 mEq/L
   Potassium                               4.5 mEq/L       3.6--5 mEq/L
   Chloride                                96 mEq/L        98--110 mEq/L
   CO2                                     19 mEq/L        25 mEq/L
   BUN                                     17 mg/dL        25 mg/dL
   Creatinine                              0.96 mg/dL      1.0 mg/dL
   Anion gap                               15 mEq/L        10--12 mEq/L
   Lactic acid                             4.4 mmol/L      \<2.0 mmol/L
   Troponin                                4.2 ng/mL       \<0.03 ng/mL
   Calcium                                 6.6 mg/dL       8 mg/dL
   Ionized calcium                         \<1.0 mmol/L    1.1 mmol/L
   AST                                     372 U/L         45 U/L
   ALT                                     214 U/L         40 U/L
   ALP                                     156 U/L         100 U/L
   T. bilirubin                            1.0 mg/dL       1.0 mg/dL
   CPK                                     203 IU/L        50 IU/L

ABG: arterial blood gas.
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